Alexandre Cc Vieira

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6893027/publications.pdf

Version: 2024-02-01

21	669	567281 15	794594 19
papers	citations	h-index	g-index

21	21	21	1066
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis. International Journal of Pharmaceutics, 2018, 536, 478-485.	5.2	101
2	Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Design, Development and Therapy, 2016, Volume 10, 2467-2475.	4.3	77
3	Solid dispersion of efavirenz in PVP K-30 by conventional solvent and kneading methods. Carbohydrate Polymers, 2014, 104, 166-174.	10.2	61
4	Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment. Nanomedicine, 2017, 12, 2721-2736.	3.3	60
5	Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 653-663.	2.8	59
6	Folate-targeted nanostructured lipid carriers for enhanced oral delivery of epigallocatechin-3-gallate. Food Chemistry, 2017, 237, 803-810.	8.2	40
7	pH-responsive chitosan based hydrogels affect the release of dapsone: Design, set-up, and physicochemical characterization. International Journal of Biological Macromolecules, 2019, 133, 1268-1279.	7.5	39
8	Development of PLGA nanoparticles loaded with clofazimine for oral delivery: Assessment of formulation variables and intestinal permeability. European Journal of Pharmaceutical Sciences, 2018, 112, 28-37.	4.0	31
9	Study of stability and drug-excipient compatibility of diethylcarbamazine citrate. Journal of Thermal Analysis and Calorimetry, 2013, 111, 2179-2186.	3.6	30
10	Multicomponent systems with cyclodextrins and hydrophilic polymers for the delivery of Efavirenz. Carbohydrate Polymers, 2015, 130, 133-140.	10.2	29
11	Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells. International Journal of Nanomedicine, 2016, 11, 2601.	6.7	29
12	Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages. Carbohydrate Polymers, 2021, 252, 116978.	10.2	19
13	Rational and precise development of amorphous polymeric systems with dapsone by response surface methodology. International Journal of Biological Macromolecules, 2015, 81, 662-671.	7.5	18
14	Overcoming clofazimine intrinsic toxicity: statistical modelling and characterization of solid lipid nanoparticles. Journal of the Royal Society Interface, 2018, 15, 20170932.	3.4	17
15	pH-sensitive nanoparticles for improved oral delivery of dapsone: risk assessment, design, optimization and characterization. Nanomedicine, 2017, 12, 1975-1990.	3.3	15
16	Quality by Design: Discussing and Assessing the Solid Dispersions Risk. Current Drug Delivery, 2014, 11, 253-269.	1.6	12
17	Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy. Pharmaceutics, 2020, 12, 75.	4.5	11
18	Nanosystems as modulators of intestinal dapsone and clofazimine delivery. Biomedicine and Pharmacotherapy, 2018, 103, 1392-1396.	5.6	9

#	Article	IF	Citations
19	Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?. Pharmaceutics, 2020, 12, 1202.	4.5	9
20	Oral Administration of Nanoparticles-Based TB Drugs. , 2017, , 307-326.		3
21	Study of the effect of solvent on acetylate cashew gum-based nanoparticles properties and antimicrobial activity. Revista Materia, 2020, 25, .	0.2	0